Dare BioscienceNASDAQ: DARE

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management.

Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active ingredient as in Viagra® Provides Daré access to capital at Daré's discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active ingredient as in Viagra®

Dare Bioscience, Inc. (DARE) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of a loss of $0.57 per share. This compares to loss of $1.20 per share a year ago.

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended June 30, 2024 and provided a company update.

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024.

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Officer Lisa Walters-Hoffert - CFO Conference Call Participants Catherine Novack - Jones Trading Doug Tsao - H.C. Wainright Operator Welcome to the conference hosted by Daré Bioscience to Review the Company's Third Quarter Financial Results and to provide a General Business Update.

Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The women's health-focused biopharmaceutical company on Tuesday reported positive results from its Phase 2b RESPOND study evaluating its proprietary topical formulation of sildenafil (sildenafil cream 3.6%) as a treatment for female sexual arousal disorder (FSAD), a condition for which there is no Food and Drug Administration (FDA)-approved treatment.

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Commercial Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Catherine Novack – Jones Research Kumar Raja – ROTH Capital Kemp Dolliver – Brookline Capital Markets Doug Tsao – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended March 31, 2023, and to provide a General Business Update.